Skip to main content
. 2012 Oct;97(10):1562–1569. doi: 10.3324/haematol.2011.060087

Figure 2.

Figure 2

Kaplan-Meier survival curves for pre-treated CP CML patients who received SD imatinib (400 mg QD, arm A) or HD imatinib induction (800 mg for 6 months, followed by imatinib 400 mg QD thereafter; arm B). Overall survival (A), progression-free survival (B), event-free survival (C). Events were defined as follows: death from any course during treatment, progression to accelerated phase or blast crisis, loss of a complete haematologic response, loss of a MCyR.